FONT-SIZE Plus   Neg

Nucor Expects Q3 EPS Of $0.35 - $0.40 - Quick Facts

Nucor Corporation(NUE), a manufacturer of steel products, Tuesday said it expects its third-quarter earnings to be in range of $0.35 to $0.40 per share, an increase from $0.35 per share reported during the corresponding quarter last year. This year's projected results include an $18 million LIFO credit, compared with $84 million a year ago. Last year results also included a non-cash charge of $28.2 million, the company said. Analysts expect the company to report earnings of $0.38 per share. Analysts' estimates typically exclude one-time items.

The company said the overall operating performance in the steel mills segment has improved, and sheet steel profitability improved as a result of competitor supply disruptions, customer inventory restocking and some market demand improvement. Structural steel results improved due to Nucor Yamato Steel's higher production, the company added. The company's raw materials segment is expected to report weaker results in the third quarter, mainly due to increased start-up costs at its plant in Louisiana, whose production is expected to begin soon.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Visa Inc. (V) on Monday reported an increase in profit for the fourth quarter, as revenues jumped driven largely by increase in customer spending and inclusion of Europe business. Earnings and revenues trumped Wall Street expectations. Foster City, California-based Visa's fourth-quarter profit rose... As Sony Corp. prepares to launch the new PlayStation 4 Pro gaming console on November 10, several new games that are compatible with the console have also been confirmed for launch. Game developers are readying to provide PlayStation 4 Pro support for many games on PS4. Shares of Advaxis Inc. dropped more than 13 percent in pre-market activity before paring losses to just more than 5 percent after the company said that it was not able to complete the second stage of the Phase 2 GOG-0265 trial as designed due to a clinical hold that affected its clinical development programs last year.
comments powered by Disqus
Follow RTT